[General pharmacological properties of methiazinic acid (16091 RP)].
D000038:Abscess / Q000517:prevention & control; D000085:Acetates / Q000494:pharmacology* / Q000633:toxicity; D000700:Analgesics / Q000494:pharmacology; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D001168:Arthritis / Q000517:prevention & control; D001341:Autonomic Nervous System / Q000187:drug effects; D001920:Bradykinin / Q000037:antagonists & inhibitors; D002319:Cardiovascular System / Q000187:drug effects; D002490:Central Nervous System / Q000187:drug effects; D010856:Columbidae; D003864:Depression, Chemical; D004231:Diuresis / Q000187:drug effects; D004285:Dogs; D004487:Edema / Q000517:prevention & control; D004890:Erythema / Q000517:prevention & control; D005122:Exudates and Transudates; D005260:Female; D006099:Granuloma / Q000517:prevention & control; D006168:Guinea Pigs; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology; D051379:Mice; D009132:Muscles / Q000494:pharmacology; D010538:Peritonitis / Q000517:prevention & control; D010640:Phenothiazines / Q000494:pharmacology* / Q000633:toxicity; D010653:Phenylbutazone / Q000494:pharmacology; D011817:Rabbits; D011837:Radiation-Protective Agents / Q000494:pharmacology; D051381:Rats; D012137:Respiratory System / Q000187:drug effects; D012702:Serotonin Antagonists; D014466:Ultraviolet Rays
D000085:Acetates; D000700:Analgesics; D000893:Anti-Inflammatory Agents; D006634:Histamine H1 Antagonists; D010640:Phenothiazines; D011837:Radiation-Protective Agents; D012702:Serotonin Antagonists; D010653:Phenylbutazone; D001920:Bradykinin; D007213:Indomethacin
Propriétés pharmacologiques générales de l'acide métiazinique (16091 R.P)